Quick takes on the Social Signals from #ASCO26. 🧬 RASolute-302: @marklewismd 's tweet regarding the standing ovation for RASolute-302 really made that trial stand out. The momentum here was massive, fueled by high expectations from the @RevMedicines PR, #AACR26 presentations,and the high-profile Ben Sasse interviews. ⚔️ PROTEUS: One of the more interesting trials from a social media perspective, as the radiation oncology community on X was highly critical of the trial's surgical paradigm. 🔄 CROWN: Felt a bit like an incredible replay of the Plenary from years ago—steady, practice-confirming data. 🎬 HARMONi-6: Perhaps the most compelling narrative twist. The discussant, Dr. Julie Brahmer, masterfully set up the Plenary audience using The Devil Wears Prada as a research metaphor. It begs the question: Is VEGF back? 🚀 LIBRETTO-432: A massive surprise for many attendees. Lung cancer specialists were thrilled about @LillyOncMed selpercatinib in the adjuvant setting for RET-positive NSCLC. The core takeaway from @christine_lovly presentation was loud and clear: "This is why we test." 🔬 OPTIMA: Really got the breast cancer community excited about using @Veracyte 's test to safely reduce the chemotherapy burden for many of their patients. 📦 WU-KONG28: Had such an interesting vibe. Great data from @Dizal_Global , but it leaves the KOLs asking the same commercial question: Why isn't this readily available to patients in the US yet? Follow the #ASCO26 Pre and Post highlights here: kolpulse.com/kol-pulse-asco2…

Divarasib vs Sotorasib? Lung Cancer KOL Reactions at #ESMO26 hubs.ly/Q04CY6dG0

Interactive KOL Network Analysis Tool: View the Retweet Networks for the top Lung Cancer Influencers at #ESMO26 kolpulse.com/esmo26-lung-att…

🫁 ESMO 2026: Major Advances in Thoracic Oncology — I picked 10 Key Clinical Trials presented at #ESMO26 worthy of attention. 🔴 DeLLphi-305 | NEJM | LBA3 🌍 Global, Phase III | ES-SCLC Tarlatamab + durvalumab maintenance post-1L chemo-IO significantly improved survival vs durvalumab alone. • Median OS: 21.1 vs 12.7 months (HR 0.42, P<0.001) • Median PFS: 7.4 vs 1.9 months (HR 0.34) A remarkable OS benefit that could redefine 1L maintenance in ES-SCLC. CRS management remains crucial. 💊 KRAScendo 1 | NEJM | LBA5 🌍 Global, Phase III | Pretreated KRAS G12C NSCLC Divarasib vs sotorasib/adagrasib demonstrated major improvements in both PFS and OS. • Median PFS: 9.8 vs 5.7 months (HR 0.58) • Median OS: 17.7 vs 12.0 months (HR 0.56) • ORR: 58% vs 32% A major milestone for next-gen KRAS G12C inhibitors, offering a potent post-g12ci option. 🎯 SAFFRON | NEJM | LBA6 🌍 Global, Phase III | EGFRm, MET-driven NSCLC post-osimertinib Osimertinib + savolitinib vs platinum-based chemo: • Median PFS: 7.6 vs 5.4 months (HR 0.55) • Median OS: 17.8 vs 12.9 months (HR 0.68) • ORR: 51% vs 27% Validates dual EGFR/MET targeting in acquired MET-driven resistance. Molecular profiling is essential. 💉 OptiTROP-Lung06 | NEJM | LBA66 🇨🇳 Chinese Predominant, Phase III | 1L PD-L1-negative nonsquamous NSCLC Sacituzumab tirumotecan (sac-TMT, TROP2 ADC) + pembro vs chemo + pembro: • Median PFS: 15.0 vs 5.7 months (HR 0.49, P<0.0001) • ORR: 50.2% vs 47.3% • Grade ≥3 AEs: 47.6% vs 60.6% Impressive PFS extension with a novel ADC-IO combination. OS and long-term safety data awaited. 🛡️ NEOTORCH | Annals of Oncology | LBA64 🇨🇳 Chinese Population, Phase III | Resectable stage II–III NSCLC Perioperative toripalimab + chemo vs chemo alone: • Median EFS: NR vs 20.2 months (HR 0.52) • OS HR: 0.66 (P=0.0072) • pCR: 25.6% vs 1.2% | MPR: 47.2% vs 9.2% Durable EFS and robust OS benefit further solidify perioperative IO in resectable NSCLC. 📈 PERSEE | Annals of Oncology | 2614O 🇫🇷 French Population, Phase III | 1L NSCLC, PD-L1 ≥50% Pembrolizumab + chemo vs pembrolizumab monotherapy: • Median PFS: 16.1 vs 6.9 months (HR 0.56) • ORR: 77.5% vs 50.3% • Median OS: 50.2 vs 29.9 months (HR 0.77, NS) Significant PFS doubling, though patient selection in PD-L1 high cohorts remains nuanced. ⏱️ DeLLphi-304 | Annals of Oncology | 3808O 🌍 Global, Phase III | Relapsed SCLC post-platinum Tarlatamab vs investigator’s choice chemo: • Median OS: 13.6 vs 8.4 months (HR 0.69) • Median PFS: 4.2 vs 3.2 months (HR 0.69) • ORR: 35% vs 20% Extended follow-up confirms a durable 5.2-month OS advantage, cementing DLL3 T-cell engagers in 2L+ SCLC. ⚔️ PANKU-Lung01 | The Lancet | LBA71 🇨🇳 Chinese/Asian, Phase III | EGFRm NSCLC post-3rd gen TKI Izalontamab brengitecan (EGFR/HER3 bispecific ADC) vs platinum chemo: • Median PFS: 11.1 vs 5.7 months (HR 0.40, P<0.001) • ORR: 60.2% vs 34.5% • Grade ≥3 TRAEs: 79% vs 62% Striking PFS benefit showcasing bispecific ADCs for post-TKI EGFRm NSCLC. Toxicity monitoring remains key. 🧪 HERON-Lung01 | The Lancet | LBA72 🇨🇳 Chinese/Asian, Phase III | EGFRm NSCLC post-EGFR TKI Ruzaltatug rezetecan (SHR-A2009, HER3 ADC) vs platinum chemo: • Median PFS: 8.3 vs 5.4 months (HR 0.47) • ORR: 60.0% vs 34.3% • Grade ≥3 TRAEs: 40.7% vs 38.9% Another strong HER3 ADC result in post-TKI progression, notably without mandatory HER3 pre-selection. 🔬 NeoCOAST-2 | Nature | 4244RO 🌍 International, Phase II | Resectable stage IIA–IIIB NSCLC Perioperative durvalumab + chemo + oleclumab, monalizumab, or Dato-DXd: • 24-month EFS: 70.5%, 75.7%, and 77.9% across arms • ctDNA clearance after C3: 50.9%, 54.5%, and 72.5% • Early ctDNA clearance strongly correlated with EFS (HR 0.22) Dato-DXd arm showed exceptional molecular response, underscoring ctDNA as a key surrogate biomarker. #ESMO26 #LungCancer #ThoracicOncology #NSCLC #SCLC #ADC #Immunotherapy

My thoughts from the #ESMO26 conference on thoracic oncology 1️⃣ T-cell engagers are changing SCLC — DeLLphi-305's 58% mortality reduction in 1L maintenance and DeLLphi-304's mature, approved relapsed benefit. 2️⃣ ADCs and rational EGFR/MET combinations are expanding post-resistance options — but watch the fine print: China-only populations, interim OS, and (for PANKU) heavy myelosuppression. 3️⃣ Perioperative IO and ctDNA are reshaping early-stage care — NEOTORCH is OS-positive at final analysis; NeoCOAST-2 and MDT-BRIDGE show ctDNA and MDT-adaptive strategies worth testing in phase III. An outstanding year for thoracic oncology — with the usual reminder: interim OS, single-arm designs, and regional populations temper the headlines.

New biomarker analysis from TALAPRO-2 @TheLancetOncol Baseline ctDNA and early dynamics correlated with rPFS, adding prognostic value beyond PSA in some patients Integrating ctDNA, circulating tumour cells and PSA warrants further exploration @OncoAlert sciencedirect.com/science/ar…

Final analysis of DREAMM-3 #mmsm @BloodCancerJnl ✅ As monotherapy, belantamab is not better than Pom/Dex (no difference in PFS, PFS2 and OS) even with longer follow up ✅ About 20% (24 of 122) of patients who had a first grade ≥2 eye exam finding still hadn’t recovered from it at their last visit ➡️ rdcu.be/rypZoXm45vba

The reason why every journal needs good social media editor . Check the image and check article tital @nejm

AI in Oncology 2026: 6 Community Trends | KOL Pulse hubs.ly/Q04CY4NV0

Doctors read these CT scans as normal. An AI model looked at the same scans and flagged pancreatic cancer anyway. In a study published in Gut, researchers took scans from people who were later diagnosed with pancreatic cancer and compared them with scans from people who stayed cancer free. The AI picked out the cancer on about 73% of the earlier scans. Experienced radiologists caught about 39%. On average the AI saw something about 16 months before the diagnosis. The catch: this looked backward at old scans. It still needs testing going forward, in people at higher risk, before anyone uses it on patients. Study: pubmed.ncbi.nlm.nih.gov/4204…

🚨 ENZARAD (ANZUP 1303): 2 years of enzalutamide did not improve metastasis-free survival when added to RT + ADT in high-risk/locally advanced #prostatecancer 🚨 @JCO_ASCO 👥 802 pts, high-risk localized or locally advanced PCa (incl cN1) 📊 Open-label phase 3 RCT, definitive prostate RT + 24 mo ADT 💊 Enzalutamide 160mg daily x24 mo vs older NSAA x6 mo ⏱️ Median f/u 92 mo ✅ 8-yr MFS on conventional imaging 74% vs 72%, HR 0.88 (0.67-1.15), P=0.34, not significant ✅ No OS benefit ✅ Prespecified subgroup w/ planned pelvic nodal RT (n=324): HR 0.47 (0.29-0.76), Padj=0.004 ⚠️ Subgroup signal is hypothesis-generating; grade 3-5 AEs 46% in both arms 🎯 Enzalutamide on top of RT + 2 yr ADT did not improve outcomes overall, potential signal with pelvic nodal RT subgroup 🔗 doi.org/10.1200/JCO-26-01794 @urotoday @UrologyTimes @PCF_Science @SbrtSean @ChrisSweens1 @Prof_IanD @UroOnc @SUO_YUO

This is also true of pharma trials.

Great paper on benefit of Tam-peli easily beating SOC topotecan in 2nd line ES-SCLC…. But wrong figures attached by NEJM on sac-TMT..now fixed it! (Guess it is not only me struggling w ADC nicknames…) Excellent data by Dr Zhao et al and can hardly wait to see one of these agents approved as study also shows sobering new reality for us- w tarla moving into maintenance and lurbi “ousted”, are we supposed to go back to topotecan’t (as famously coined by Dr. Socinski? @CoreyLange28917 )? With pitiful data as seen in this study: 60% of pts progress on topo by 3 months, ORR<10% and with grade 3 or higher AEs at 75% (!) and very burdensome schedule i just can’t…and our patients shouldn’t.. #lcsm

The #SABCS26 abstract titles are out! One study that particularly caught my attention is STOP-HER2, which will be presented in GS3. These results could provide crucial insights into de-escalation strategies for exceptional responders to anti-HER2 therapy. Looking forward to the data! sabcs.org/events/

People who have been in research fields develop a felt sense that most "research" (in almost any field that isn't exactingly technical) is research theater, and many superstar careers enjoy star status not because of a unique connection to the truth but because of a unique connection with an audience. No one really has the time or stature to, from a position of objectivity and trust, bring popular researchers to heel. But it will get increasingly hard to hide from serious critique. The machines can do critique now, at the level of depth and rigor previously only possible for the academically deranged. We're going to have to revise a lot of what we "know" about the world that isn't really knowledge but is actually just received popular consensus - like floating voltages without grounding wires. The grounding wires are coming.

Top 25 Most Discussed Trials at #ESMO26 👉Lung Cancer owned the conversation at #ESMO26, followed by melanoma with INTerpath-001 — then GU surged in with VOLGA and the peri-op bladder trials. Top 25👉 hubs.ly/Q04CX0N90

An important statistical consideration: - monarchE: OS was a prespecified, alpha-controlled key secondary endpoint; P=0.027 (crossed the 0.0434 boundary). - NATALEE: 6-year OS was descriptive, with no alpha allocated (nominal 1-sided P=0.019).

AstraZeneca launches $1.5B cost-saving plan to reinvest in drug pipeline $AZN firstwordpharma.com/story/83…

This is an important release in @JCO_ASCO in conjunction with #ESMO26 #DASL HiCaP trial. Identifying pts who benefit the most from intensified treatment is a work in progress. @ASCO @myESMO @ChrisSweens1 #ENZARAD @Prof_IanD et al. @OncoAlert ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer | Journal of Clinical Oncology ascopubs.org/doi/pdf/10.1200…

Just learned via Retraction Watch that Scientific Reports is on hold and will not appear on PubMed. In January this year I wrote an article reviewing the excellent team's™ work, my conclusion: